# **U** NOVARTIS

Novartis India Limited Registered Office: Inspire BKC Part of 601 & 701 Bandra Kurla Complex Bandra (East) Mumbai – 400 051 Maharashtra, India Tel +91 22 50243000 Fax +91 22 50243010 Email: india.investors@novartis.com CIN No. L24200MH1947PLC006104 Website: www.novartis.in

December 4, 2019

The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

## Sub.: Disclosure of related party transactions for the half year ended on September 30, 2019

### Ref.: 1. <u>Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations</u> <u>and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")</u> 2. Scrip Code: 500672

Dear Sir/ Madam,

Apropos the subject matter quoted above, please find enclosed herewith the disclosure of Related Party Transactions on a standalone basis, in format as specified in the relevant accounting standards for the half year ended on September 30, 2019.

The above is for your information and the same is also available on the Company's website i.e. www.novartis.in

Thanking you

Yours sincerely,

For-Novartis India Limited . . in Trivikram Gude

Company Secretary & Compliance Officer

#### (A) Enterprise where control exists

Holding Company and Ultimate Holding Company

Novartis AG, Basel, Switzerland

#### (B) Other Related Parties with whom the company had transactions during the year and/or the previous year

(i) Fellow Subsidiaries

Novartis Healthcare Private Limited, India Novartis Holding AG, Switzerland Novartis Pharma AG, Switzerland Sandoz Private Limited, India

 List of other related parties (Post-employment benefit plan of Novartis India Limited) Novartis India Limited Employees' Provident Fund

(C)Key Management<br/>PersonnelMr. Trivikram Guda - Company Secretary & Compliance Officer<br/>Mr. Milan Paleja - Managing Director (upto May 31, 2019)<br/>Mr. Sanjay Murdeshwar - Managing Director (w.e.f. June 15, 2019)<br/>Ms. Monaz Noble - Chief Financial Officer (Upto May 31, 2019)<br/>Mr. Felix Doss - Chief Financial Officer (w.e.f. June 1, 2019)

Dr. Rajendra Mehrotra - Independent Director Mr. Jai Hiremath - Independent Director Ms. S. Martyes - Independent Director Mr. Christopher Snook - Director (Chairman) Ms. Monaz Noble - Director

| Half year ended 30 Sep 2019<br>in ₹ million |
|---|
|   |
| 174.:                                       |
| 13.   |
| 67.   |
|   |



|  | Half year ended 30 Sep 2019<br>in ₹ million |
|--|---|
| Purchases of Stock-in-Trade  |   |
| Novartis Pharma AG   | 541.4                                       |
|  | 541.4                                       |
| Sale of Services   |   |
| Novartis Healthcare Private Limited  | 37.2  |
| Novartis Pharma AG   | 15.0  |
| Sandoz Private Limited   | 13.7  |
|  | 65.9  |
| Commission Income  |   |
| Novartis Healthcare Private Limited  | 137.2                                       |
|  | 137.2                                       |
| Services Availed   |   |
| Novartis Healthcare Private Limited  | 17.3  |
| Novartis Pharma AG   | 0.9   |
|  | 18.2  |
| Purchase of Restricted Shares of Novartis AG on behalf of employees of the | e Company by                                |
| Novartis Holding AG  | 3.1   |
|  | 3.1   |
|  |   |
| Expenses paid by related party on behalf of the Company                    | 21  |
| Novartis Healthcare Private Limited  | 2.1   |
|  | 2.1   |
| Expenses paid by the Company on behalf of the related party                |   |
| Sandoz Private Limited   | 0.002                                       |
|  | 0.002                                       |



|   | Half year ended 30 Sep 2019<br>in ₹ million |
|---|---|
| Balances as at the half year end -                          |   |
| Outstanding Receivables                                     |   |
| Novartis Healthcare Private Limited                         | 104.9                                       |
| Novartis Pharma AG  | 1.4   |
| Novartis Holding AG   | 4.0   |
| Sandoz Private Limited                                      | 6.3   |
|   | 117.  |
|   | Half year ended 30 Sep 2019                 |
|   | in ₹ million                                |
| Outstanding Payables  |   |
| Novartis Healthcare Private Limited                         | 889.1                                       |
| Novartis Pharma AG  | 292.0                                       |
|   | 1,181.7                                     |
| (c) Post Employment Benefit Plans of Novartis India Limited |   |
|   | Half year ended 30 Sep 2019<br>in ₹ million |
| Contribution to In-house Trust for Post Employment Benefits |   |
| Novartis India Limited Employees' Provident Fund            | 66.4  |
| (d) Key Management Personnel Compensation                   |   |
|   | Half year ended 30 Sep 2019                 |
|   | in ₹ million                                |
| Short-term employee benefits                                | 8.9   |
| Post-employment benefits                                    | 0.  |
| Commission/ Sitting Fees to Independent Directors           | 0.  |
| Total compensation  | 10.   |

Notes:

1) No amounts have been written off/provided for or written back in respect of amounts receivable from or payable to the related parties.

2) Outstanding balances at the half year-end are unsecured and interest free and settlement occurs in cash.

